Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001437749-25-036005
Filing Date
2025-11-21
Accepted
2025-11-21 16:32:31
Documents
18
Period of Report
2025-09-08
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K/A nrxp20251118_8ka.htm   iXBRL 8-K/A 38674
2 EXHIBIT 23.1 ex_890964.htm EX-23.1 3009
3 EXHIBIT 99.1 ex_889984.htm EX-99.1 250822
4 EXHIBIT 99.2 ex_889993.htm EX-99.2 235946
5 EXHIBIT 99.3 ex_889994.htm EX-99.3 299902
10 a01.jpg GRAPHIC 12569
  Complete submission text file 0001437749-25-036005.txt   1069686

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20250908.xsd EX-101.SCH 4042
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20250908_def.xml EX-101.DEF 14165
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20250908_lab.xml EX-101.LAB 18670
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20250908_pre.xml EX-101.PRE 14252
20 EXTRACTED XBRL INSTANCE DOCUMENT nrxp20251118_8ka_htm.xml XML 4996
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

EIN.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-38302 | Film No.: 251508468
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)